WATCH: Vamorolone Clinical Trials in Duchenne - Webinar Recording - Parent Project Muscular Dystrophy
Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study - Jett Foundation
VISION-DMD newsletter launched at Phase 2 of clinical trial of Vamorolone - Action Duchenne
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study | PLOS Medicine
Mechanism of Action - ReveraGen BioPharma
Participants Sought for Clinical Trial to Test Vamorolone in DMD - Muscular Dystrophy Association
Vamorolone | C22H28O4 | CID 3035000 - PubChem
Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit: Molecular Therapy
Vamorolone treatment following disease induction reduces the severity... | Download Scientific Diagram
Vamorolone inhibits inflammatory signaling in macrophage and heart... | Download Scientific Diagram
![Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube](https://i.ytimg.com/vi/h1owg21J0Wc/maxresdefault.jpg "Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube")
Webinar] Vamorolone (VBP15) Clinical Trials in Duchenne - January 2017 - YouTube
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes - ScienceDirect
Investigational steroid mirrors prednisone's benefits while taming its side effects | Children's National
Vamorolone Trial for DMD Finishes Pivotal First Part, Results Awaited
Therapeutic: vamorolone for Duchenne muscular dystrophy
In DMD Trial, Vamorolone Shows Efficacy and Safety Over 48 Weeks
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy - Jett Foundation
Vamorolone - Wikipedia
Vamorolone demonstrates efficacy, safety for boys with Duchenne muscular dystrophy
Bone Biomarkers Maintained With Vamorolone Over Prednisone: Trial Data | Muscular Dystrophy News
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug - ScienceDirect
Vamorolone Post-Trial Access
Santhera and ReveraGen: Vamorolone NDA Mid-Cycle Review with FDA – Defeat Duchenne Canada
Summary of vamorolone clinical trials completed. | Download Scientific Diagram
VISION-DMD End Event: Vamorolone Clinical Trial Results • World Duchenne
